Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.23.3
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues        
Services $ 37,688 $ 9,881 $ 93,207 $ 80,181
Royalty 0 2,911 0 2,911
Product 127,523 19,922 438,122 103,585
Total Revenues 165,211 32,714 531,329 186,677
Operating Expenses        
Research and development 4,650,658 4,002,212 15,007,623 11,202,902
General and administrative 2,599,908 2,498,506 7,826,568 7,855,184
Sales and marketing 1,567,700 1,524,952 4,944,259 4,897,999
Total Operating Expenses 8,818,266 8,025,670 27,778,450 23,956,085
Operating Loss (8,653,055) (7,992,956) (27,247,121) (23,769,408)
Other Income (Expenses)        
Grant income 48,656 171,439 214,451 564,879
Loss on disposal of fixed assets (15,913) 0 (15,913) 0
Interest income 230 46,945 84,987 58,108
Interest expense (53,980) (37,699) (163,623) (115,860)
Gain on change in fair value of warrant liability 220,874 0 249,845 0
Total Other Income 199,867 180,685 369,747 507,127
Net Loss (8,453,188) (7,812,271) (26,877,374) (23,262,281)
Net Loss Attributable to Non-Controlling Interest 82,887 69,305 256,546 235,584
Net Loss Attributable to VolitionRx Limited Stockholders (8,370,301) (7,742,966) (26,620,828) (23,026,697)
Other Comprehensive Income (Loss)        
Foreign currency translation adjustments 31,291 71,027 12,525 167,220
Net Comprehensive Loss $ (8,421,897) $ (7,741,244) $ (26,864,849) $ (23,095,061)
Net Loss Per Share - Basic and Diluted Attributable to VolitionRx Limited $ (0.11) $ (0.14) $ (0.39) $ (0.42)
Weighted Average Shares Outstanding        
- Basic and Diluted 78,176,859 56,120,079 68,494,766 54,603,929